Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Core Insights - Propanc Biopharma, Inc. has published significant findings regarding the impact of proenzymes on pancreatic ductal adenocarcinoma (PDAC) fibroblasts, highlighting the potential of PRP as a disruptor of the tumor microenvironment (TME) [1][3] - The company plans to conduct a Phase 1b study in Q3 2026 to evaluate PRP's efficacy in advanced cancer patients, particularly those with solid tumors, including PDAC [4] Company Overview - Propanc Biopharma, Inc. is focused on developing novel treatments for chronic diseases, specifically targeting cancer recurrence and metastasis through proenzyme activation [5] - The lead product candidate, PRP, consists of two bovine-derived pancreatic proenzymes, trypsinogen and chymotrypsinogen, which have shown efficacy in cancer treatment [1][5] Industry Context - PDAC is one of the most aggressive and deadliest forms of cancer, with projections indicating it may become the second leading cause of cancer-related deaths by 2030 [2] - The disease is characterized by late-stage diagnosis, limited treatment options, and poor prognosis, underscoring the need for innovative therapeutic strategies [2]